# US 11,110,199 B2 · Methods for host cell homing and dental pulp regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,110,199 B2
- Document ID: US11110199B2
- Status: Granted
- Kind: B2
- Application number: 16/353,834
- Filed: 2019-03-14
- Published: 2019-07-11
- Granted: 2021-09-07
- Earliest claimed: 2013-04-12
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: Helen H. Lu; Sagaw Prateepchinda; Gunnar Hasselgren
- Web page: https://patentgrep.com/patent/US11110199B2

## CPC

- A61L 27/225: {Fibrin; Fibrinogen}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61L 27/16: obtained by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/3808: {Endothelial cells}
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/3865: {Dental/periodontal tissues}
- A61L 27/48: with macromolecular fillers
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- C12N 5/0664: {Dental pulp stem cells, Dental follicle stem cells}
- A61L 2300/406: Antibiotics
- A61L 2300/64: Animal cells
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L 2430/12: for dental implants or prostheses
- C12N 2533/50: Proteins
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Hydrogel-based scaffolds useful for promoting pulp cell growth and biosynthesis, regulating pulp cell migration and morphology, or both as well as methods for their production and use are provided.

## Claims

### Claim 1

A hydrogel-based scaffold for dental pulp formation, said scaffold comprising
a biosynthetic hydrogel of polymer, fibrinogen, and 1.0-2.0% v/v of PEG-diacrylate,
wherein fibrinogen is present in the hydrogel-based scaffold at a concentration of 0.5-1.0% w/v for promoting pulp cell growth and biosynthesis, regulating pulp cell migration and morphology, or both.

### Claim 2 (depends on 1)

The hydrogel-based scaffold of claim 1 wherein the polymer comprises polyethylene glycol.

### Claim 3 (depends on 1)

The hydrogel-based scaffold of claim 1 which comprises an intact fibrinogen or a fibrinogen fragment.

### Claim 4 (depends on 1)

The hydrogel-based scaffold of claim 1 further comprising additional PEG-diacrylate from 1.7% to 3.2% w/v.

### Claim 5 (depends on 1)

The hydrogel-based scaffold of claim 1 which is injectable.

### Claim 6 (depends on 1)

The hydrogel-based scaffold of claim 1 which solidifies in vivo.

### Claim 7 (depends on 1)

The hydrogel-based scaffold of claim 1 which solidifies in vivo with non-toxic components.

### Claim 8 (depends on 1)

The hydrogel-based scaffold of claim 1 wherein the fibrinogen concentration is at least 0.8% w/v.

### Claim 9 (depends on 1)

The hydrogel-based scaffold of claim 1 further comprising an antibiotic.

### Claim 10 (depends on 1)

The hydrogel-based scaffold of claim 1 further comprising stem cells for tooth pulp repair and regeneration and/or dental pulp cells and/or endothelial cells.